Orfiril Long (Sodium Valproate)

Sodium valproate raises brain levels of the inhibitory neurotransmitter GABA and modulates voltage‑gated sodium channels, which together calm neuronal firing and help prevent the abnormal electrical activity that leads to seizures and mood swings.

The appropriate dose of Orfiril Long is individualized by the prescribing clinician based on the patient’s age, weight, seizure type, and response to therapy. Dosage adjustments are made according to clinical judgment and therapeutic monitoring.

Sodium valproate is classified as Pregnancy Category D, indicating evidence of fetal risk, particularly neural‑tube defects. It should be avoided in pregnancy unless no safer alternative exists. Breastfeeding is not recommended because the drug is excreted in milk.

To order Orfiril Long, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Compared with agents such as carbamazepine or lamotrigine, sodium valproate offers broad-spectrum seizure control, covering both generalized and focal seizures, but it carries a higher risk of hepatic and hematologic adverse effects, especially in women of child‑bearing age.

Orfiril Long tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children.

Orfiril Long is taken orally as an extended‑release tablet, usually once or twice daily as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed to maintain the extended‑release profile.

Serious risks include acute liver failure, pancreatitis, severe skin reactions such as Stevens‑Johnson syndrome, thrombocytopenia, and hyperammonemic encephalopathy. Patients should be monitored regularly for signs of these conditions and seek immediate medical attention if they occur.

Orfiril Long is contraindicated in patients with known hypersensitivity to sodium valproate, those with severe hepatic disease, urea cycle disorders, or mitochondrial disorders such as POLG mutations. Caution is also advised for women of child‑bearing potential due to teratogenic risk.